ATE411015T1 - Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien - Google Patents

Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien

Info

Publication number
ATE411015T1
ATE411015T1 AT04821452T AT04821452T ATE411015T1 AT E411015 T1 ATE411015 T1 AT E411015T1 AT 04821452 T AT04821452 T AT 04821452T AT 04821452 T AT04821452 T AT 04821452T AT E411015 T1 ATE411015 T1 AT E411015T1
Authority
AT
Austria
Prior art keywords
fibrillogenes
pathies
amyloid
peptides
aminocyclohexane derivatives
Prior art date
Application number
AT04821452T
Other languages
English (en)
Inventor
Sandeep Gupta
Pradeep Banarjee
Debomoy Lahiri
Martin Farlow
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE411015(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of ATE411015T1 publication Critical patent/ATE411015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04821452T 2003-10-22 2004-10-22 Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien ATE411015T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51370003P 2003-10-22 2003-10-22

Publications (1)

Publication Number Publication Date
ATE411015T1 true ATE411015T1 (de) 2008-10-15

Family

ID=34885905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04821452T ATE411015T1 (de) 2003-10-22 2004-10-22 Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien

Country Status (13)

Country Link
US (1) US20050113458A1 (de)
EP (1) EP1682109B1 (de)
JP (1) JP2007509165A (de)
CN (1) CN1870984A (de)
AR (1) AR046601A1 (de)
AT (1) ATE411015T1 (de)
AU (1) AU2004316119B2 (de)
CA (1) CA2540921A1 (de)
DE (1) DE602004017207D1 (de)
IL (1) IL174970A0 (de)
TW (1) TW200526194A (de)
WO (1) WO2005079779A1 (de)
ZA (1) ZA200603231B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1874282B1 (de) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
EP2089383B1 (de) 2006-11-09 2015-09-16 Probiodrug AG 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
ES2341517B1 (es) * 2008-03-28 2011-01-25 Farmalider, S.A Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2578212B1 (de) 2010-05-24 2016-07-06 Farmalider, S.A. Verbindung mit hemmung der aktivierung des enzyms erk1/2 zur verwendung bei der behandlung neurogenerativer erkrankungen
MX383953B (es) 2010-11-15 2025-03-14 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
MX381561B (es) 2013-12-20 2025-03-12 Agenebio Inc Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL303255A (en) 2015-12-30 2023-07-01 Corium Inc Systems and methods for long term transdermal administration
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA974518A (en) * 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
PL193237B1 (pl) * 1997-06-30 2007-01-31 Merz Pharma Gmbh & Co Kgaa Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
DE602004017207D1 (de) 2008-11-27
AU2004316119A1 (en) 2005-09-01
WO2005079779A1 (en) 2005-09-01
AU2004316119B2 (en) 2008-04-24
CA2540921A1 (en) 2005-09-01
IL174970A0 (en) 2006-08-20
CN1870984A (zh) 2006-11-29
ZA200603231B (en) 2007-11-28
US20050113458A1 (en) 2005-05-26
JP2007509165A (ja) 2007-04-12
AR046601A1 (es) 2005-12-14
EP1682109A1 (de) 2006-07-26
TW200526194A (en) 2005-08-16
EP1682109B1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
ATE411015T1 (de) Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien
EP1503795A4 (de) Verwendung von hitzschockproteinen zur verstärkung der wirksamkeit von antikörper-therapeutika
EP1968635A4 (de) Zusammensetzungen und verfahren mit und verwendung von nicht-natürlichen aminosäuren und polypeptiden
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EP1732581A4 (de) Polypeptidtransduktion und fusogene peptide
EP2102355A4 (de) Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
EP1594524A4 (de) Verwendung von tryptanthrin-verbindungen zur immunverstärkung
DE60326874D1 (de) Neue verwendung von erythropoietin in herzerkrankungen
AU2003265864A8 (en) In vivo production of cyclic peptides for inhibiting protein-protein interaction
DE602005012555D1 (de) Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon
DE602005014922D1 (de) Linearitätkorrektor mit Multiplizierung von Filtern
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
EP1735335A4 (de) Zellabtötende peptide
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
ATE524183T1 (de) Verwendung von sanglifehrin bei der hcv-therapie
DE602004023786D1 (de) Herstellung von hochreinem Alkylgallium
IL183106A0 (en) Production of proteins
DE60334255D1 (de) Verwendung von n-isopropylacrylamide zur aufbewahrung von kontaktlinsen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE502005003027D1 (de) Elektrolysezelle zur herstellung von alkalimetall
ATE478137T1 (de) Verbesserungen bei der virusproduktion
DE602004022046D1 (de) Herstellung von kleinen teilchen
EP1885372A4 (de) Verwendung von prostacyclin-analogen
ATE394424T1 (de) Herstellung von somatostatinpeptiden
ATE505484T1 (de) Trimer-proteine zur trimer-zytokine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties